Considerations in choosing a biologic in psoriatic disease from dermatology viewpoint @_AprilArmstrong @RheumNow #RNL2024 https://t.co/PHg0CBjTkC

#RNL2024 @RheumNow @_AprilArmstrong: Deucravacitinib v Apremilast Deucra: TYK2 inhibitor, approved for PsO (not yet PsA) Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum

Dr. A. Armstrong's Key Takeaways for PsO. TNFi - great in PsA and pregnancy IL-17i - robust PsO efficacy and in PsA IL-23i - robust in PsO, fewer injections, and efficacious in PsA. #RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf

Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p

Dr. A. Armstrong shares dermatology/dermatologist trends in PsO. 1. They tend to shorted then interval between injections as opposed to the amount of medication per dose. 2. Derms generally wait 6 months to switch meds 3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN

How are dermatology colleagues may frame our treatment options @_AprilArmstrong . This is helpful to consider in light of shared care discussions. The lack of love for JAKi in particular. @RheumNow #RNL2024 https://t.co/pv5EFXsXjI

When it comes to skin, this is how derms think and there is data to support this. - Dr. Amstrong on how IL-17i and IL23i are preferred over TNFi #psoriasis #RNL2024 @rheumnow https://t.co/UZWNgOljRh

Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 https://t.co/5ygHgOTfW8

Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI

#RNL2024 @RheumNow @_AprilArmstrong Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs - Fast onset - High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9

In a patient with purely skin limited plaque psoriasis without systemic involvement, what would you choose for treatment? The rheum audience poll at #RNL2024 is all over the place in their choice! Dr. Armstrong lectures on how derms think about #psoriasis @rheumnow https://t.co/4YxaJPlpa5